Extended release immunomodulatory implant to facilitate bone morphogenesis

Patent metadata

Field	Value
Publication number	US-12485011-B2
Application number	US-202117558826-A
Country	US
Kind code	B2
Filing date	Dec 22, 2021
Priority date	Apr 8, 2019
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including one or more interleukins, and an outer portion surrounding the inner portion, the outer portion including an antigen operatively arranged to activate an innate immune system.

First claim

What is claimed is:

1 . An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, comprising:
an inner portion including one or more interleukins; and an outer portion surrounding the inner portion, the outer portion including an antigen operatively arranged to activate an innate immune system; wherein the outer portion is connected to the inner portion and the antigen is present in the outer portion prior to implantation.

2 . The implant as recited in claim 1 , wherein the implant comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

3 . The implant as recited in claim 2 , wherein the implant consists of inert beta-tricalcium phosphate, calcium carbonate, silicon, and polylactic-co-glycolic acid, wherein the silicon is 1% by weight.

4 . The implant as recited in claim 1 , wherein the inner portion comprises at least one of interleukin 4, interleukin 10, and interleukin 13.

5 . The implant as recited in claim 1 , wherein the antigen comprises at least one of lipopolysaccharide and lipoteichoic acid.

6 . The implant as recited in claim 5 , wherein the antigen consists of a mixture of:
50% by weight lipopolysaccharide; and 50% by weight lipoteichoic acid.

7 . The implant as recited in claim 5 , wherein the antigen consists of 100% by weight lipopolysaccharide.

8 . The implant as recited in claim 5 , wherein the antigen consists of 100% by weight lipoteichoic acid.

9 . The implant as recited in claim 1 , wherein the inner portion comprises a first density and the outer portion comprises a second density, the first density being greater than the second density.

10 . The implant as recited in claim 1 , wherein the inner portion comprises a first porosity and the outer portion comprises a second porosity, the second porosity being greater than the first porosity.

11 . The implant as recited in claim 10 , wherein the first porosity and the second porosity are connected by one or more channels.

12 . The implant as recited in claim 1 , wherein the inner portion comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite, impregnated with the one or more interleukins.

13 . The implant as recited in claim 1 , wherein the inner portion comprises:
an innermost portion including interleukin 10 and interleukin 13; and an inner layer including interleukin 4.

14 . The implant as recited in claim 1 , wherein:
the inner portion comprises hydroxyapatite; and the outer portion comprises:
an inner layer including beta-tricalcium phosphate including one or more interleukins; and
an outer layer including at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma.

15 . An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, comprising:
an implant matrix including a first material, the implant matrix including:
an inner portion including at least one of interleukin 4, interleukin 10, and interleukin 13; and
an outer portion including at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma;
wherein the outer portion is connected to at least 30% of an outer surface of the inner portion.

16 . The implant as recited in claim 15 , wherein the first material comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

17 . The implant as recited in claim 16 , wherein the first material consists of inert beta-tricalcium phosphate, calcium carbonate, silicon, and polylactic-co-glycolic acid, wherein the silicon is 1% by weight.

18 . The implant as recited in claim 16 , wherein the inner portion is impregnated with the at least one of interleukin 4, interleukin 10, and interleukin 13.

19 . The implant as recited in claim 16 , wherein the outer portion is impregnated with the at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma.

Assignees

• Suddaby Loubert S

Inventors

• Suddaby Loubert S

Classifications

• A61K31/739

  Lipopolysaccharides · CPC title

• A61K38/2026

  IL-4 · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title

• A61F2002/2835

  Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material · CPC title

• A61F2002/30011

  differing in porosity · CPC title